미국 · 보도자료 · Telix Pharmaceuticals Limited · 2026-10-06 10:30
FDA 승인 뇌암 진단제 '픽스클라라', 첫 환자 투약 개시
MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine F 18 or 18 F-FET), its FDA-approved, amino acid positron emission tomography (PET) drug for glioma (brain cancer) imaging.
Telix Pharmaceuticals Limited 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
